文献速递神经肿瘤

哥伦比亚人群癌症登记中神经系统肿瘤的生存分析

Survival of nervous system tumors in a Colombian population cancer registry.
PubMed 文献 · J Neurooncol · 2025-11-17

该研究基于哥伦比亚布卡拉曼加都市区人群癌症登记数据,回顾性纳入2003–2017年诊断的1126例中枢神经系统肿瘤患者,评估5年总生存及相关因素。结果显示5年总生存率为57.5%,恶性肿瘤为39.6%,胶质母细胞瘤预后最差(生存率20.9%,HR 9.64,p<0.001)。生存与年龄、性别、肿瘤行为、组织学亚型、部位及分化程度相关,与社会经济状况或保险类型无关。

要点

  • 胶质母细胞瘤5年生存率仅20.9%,HR 9.64,预后最差
  • 恶性肿瘤5年生存率39.6%,总体5年生存率57.5%
  • 年龄≥60岁、男性、未分化/间变性级别为独立不良预后因素

核心结论

  • 该队列中中枢神经系统肿瘤预后与年龄、性别、肿瘤行为、组织学亚型、部位及分化程度相关。
  • 过早死亡突出,需提高诊断准确性并强化登记系统纳入临床和遗传数据。

研究设计与样本

  • 回顾性队列研究,基于哥伦比亚布卡拉曼加都市区人群癌症登记数据,纳入2003–2017年诊断病例,共1126例。
  • 采用Kaplan-Meier法和Cox比例风险模型评估生存及风险比。

主要发现

  • 中位诊断年龄55岁,恶性 neoplasms 占60.04%。
  • 恶性组织学亚型中最常见为胶质母细胞瘤(27.9%),良性中最常见为脑膜瘤(80.3%)。
  • 67.58%患者死亡,每例患者平均损失21.6年寿命。
  • 5年总生存率57.5%,恶性肿瘤5年生存率39.6%。
  • 胶质母细胞瘤生存率20.9%(HR 9.64;p < 0.001)。

关键数值与推荐

  • 年龄≥60岁:HR 1.92;p < 0.001。
  • 男性:HR 1.37;p < 0.001。
  • 未分化/间变性级别:HR 7.46;p < 0.001。
  • 社会经济状况或保险类型与生存无显著关联。

临床怎么用

  • 提示应关注高龄、男性、恶性行为、未分化/间变性级别及胶质母细胞瘤患者的预后评估。
  • 登记数据可用于监测中枢神经系统肿瘤生存及过早死亡负担。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Primary tumors of the central nervous system (CNS) are rare, but they carry high morbidity and mortality. In Latin America, information on survival is limited. This study aimed to identify factors associated with survival of CNS tumors in a Colombian population. METHODS: A retrospective cohort study was conducted with data from the Population Cancer Registry of the Metropolitan Area of Bucaramanga, including cases diagnosed between 2003 and 2017. Sociodemographic and clinical variables were analyzed. Survival was assessed using the Kaplan-Meier method and Cox proportional hazards models. Overall survival at 5 years and hazard ratios (HR) were estimated. RESULTS: A total of 1126 patients were included, with a median age at diagnosis of 55 years. 60.04% were malignant neoplasms. The most frequent histological subtypes were glioblastoma (27.9% of malignant tumors) and meningioma (80.3% of benign tumors). In total, 67.58% died, with 21.6 years of life lost per patient. Overall survival at 5 years was 57.5%. Malignant tumors had a survival rate of 39.6%. Glioblastoma had the worst prognosis (20.9% survival; HR 9.64; p < 0.001). Other significant predictors were: age ≥ 60 years (HR 1.92; p < 0.001), male sex (HR 1.37; p < 0.001), undifferentiated/anaplastic grade (HR 7.46; p < 0.001). No significant association was found between survival and socioeconomic status or type of insurance. CONCLUSION: In this cohort, the prognosis of CNS tumors was associated with age, sex, tumor behavior, histological subtype, location, and degree of differentiation. The premature mortality highlights the need to improve diagnostic accuracy and strengthen population registries with clinical and genetic data.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Albarracín Cárdenas CI, Caballero Rojas H, Ochoa Vera ME, et al. Survival of nervous system tumors in a Colombian population cancer registry. J Neurooncol. 2025. PMID: 41247425. doi:10.1007/s11060-025-05313-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。